Evidence map›Paper›PMID 34708732›Full record

ReviewIndian journal of ophthalmology2021

Telemedicine in diabetic retinopathy screening in India.

Kim Ramasamy, Chitaranjan Mishra, Naresh B Kannan, P Namperumalsamy, Sagnik Sen

Abstract readReview
In one paragraph

Review in Indian journal of ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Manhattan Vision Screening and Follow-Up Study: (NYC-SIGHT)Tele-Retinal Image Findings and Importance of Photography.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2024
    Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Observational
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kim RamasamyDepartment of Retina and Vitreous Services, Aravind Eye Hospital, Madurai, Tamil Nadu, India.
Chitaranjan MishraDepartment of Retina and Vitreous Services, Aravind Eye Hospital, Madurai, Tamil Nadu, India.
Naresh B KannanDepartment of Retina and Vitreous Services, Aravind Eye Hospital, Madurai, Tamil Nadu, India.
P NamperumalsamyDepartment of Retina and Vitreous Services, Aravind Eye Hospital, Madurai, Tamil Nadu, India.
Sagnik SenDepartment of Retina and Vitreous Services, Aravind Eye Hospital, Madurai, Tamil Nadu, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With ever-growing prevalence of diabetes mellitus and its most common microvascular complication diabetic retinopathy (DR) in Indian population, screening for DR early for prevention of development of vision-threatening stages of the disease is becoming increasingly important. Most of the programs in India for DR screening are opportunistic and a universal screening program does not exist. Globally, telemedicine programs have demonstrated accuracy in classification of DR into referable disease, as well as into stages, with accuracies reaching that of human graders, in a cost-effective manner and with sufficient patient satisfaction. In this major review, we have summarized the global experience of telemedicine in DR screening and the way ahead toward planning a national integrated DR screening program based on telemedicine.

Indexed as

Diabetes MellitusDiabetic RetinopathyTelemedicineHumansIndiaMass ScreeningPrevalenceArtificial intelligencediabetes mellitusdiabetic retinopathytelemedicinetelescreeningvision threatening

Identifiers

PMID34708732
PMCPMC8725153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.